Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00058955 · ClinicalTrials.gov registry record · Phase 1
Physiological, Behavioral and Subjective Effects of Drugs (GHB)
A Phase 1 study of Sedative Abuse, sponsored by Orphan Medical.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00058955 is a Phase 1 study of Sedative Abuse that has completed, run by Orphan Medical. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00058955, a Phase 1 study of Sedative Abuse, has completed, sponsored by Orphan Medical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn more about the effects of gamma-hydroxybutyric acid (GHB) by comparing its physiological, behavioral and subjective effects with those of several other drugs.
Conditions Studied
Interventions
- DRUG sodium oxybate, triazolam and pentobarbital
Study Locations (1)
Maryland
- Johns Hopkins University School of Medicine/Bayview Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2003-08 |
| Est. Completion | 2005-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00058955
The ClinicalTrials.gov registry entry for NCT00058955 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Orphan Medical, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sedative Abuse appearing as the primary indexed condition, and to 1 intervention - of which sodium oxybate, triazolam and pentobarbital is the first listed.
NCT00058955 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00058955 about?
NCT00058955 is a clinical study titled "Physiological, Behavioral and Subjective Effects of Drugs (GHB)". The purpose of this study is to learn more about the effects of gamma-hydroxybutyric acid (GHB) by comparing its physiological, behavioral and subjective effects with those of several other drugs.
What is the current status of trial NCT00058955?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2003-08. Estimated completion is 2005-03.
What conditions does trial NCT00058955 study?
This clinical trial studies the following conditions: Sedative Abuse.
What interventions are being tested in trial NCT00058955?
The interventions under investigation include: sodium oxybate, triazolam and pentobarbital (DRUG).
Who is sponsoring clinical trial NCT00058955?
This trial is sponsored by Orphan Medical, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00058955 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.